These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 28103901)

  • 61. LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A case-control association study for Parkinson's disease.
    Gopalai AA; Lim JL; Li HH; Zhao Y; Lim TT; Eow GB; Puvanarajah S; Viswanathan S; Norlinah MI; Abdul Aziz Z; Lim SK; Tan CT; Tan AH; Lim SY; Tan EK; Ahmad Annuar A
    Mol Genet Genomic Med; 2019 Nov; 7(11):e604. PubMed ID: 31487119
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tyrosine Metabolism Pathway Is Downregulated in Dopaminergic Neurons with LRRK2 Overexpression in
    Cheng J; Wu BT; Liu HP; Lin WY
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958569
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A trojan horse for Parkinson's disease.
    Hu Y; Tong Y
    Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
    [TBL] [Abstract][Full Text] [Related]  

  • 64. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.
    Melachroinou K; Leandrou E; Valkimadi PE; Memou A; Hadjigeorgiou G; Stefanis L; Rideout HJ
    PLoS One; 2016; 11(11):e0166053. PubMed ID: 27832104
    [TBL] [Abstract][Full Text] [Related]  

  • 66. LRRK2 mediates axon development by regulating Frizzled3 phosphorylation and growth cone-growth cone communication.
    Onishi K; Tian R; Feng B; Liu Y; Wang J; Li Y; Zou Y
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18037-18048. PubMed ID: 32641508
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Axin-2 knockdown promote mitochondrial biogenesis and dopaminergic neurogenesis by regulating Wnt/β-catenin signaling in rat model of Parkinson's disease.
    Singh S; Mishra A; Mohanbhai SJ; Tiwari V; Chaturvedi RK; Khurana S; Shukla S
    Free Radic Biol Med; 2018 Dec; 129():73-87. PubMed ID: 30176346
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibition of β-catenin dependent WNT signalling upregulates the transcriptional repressor NR0B1 and downregulates markers of an A9 phenotype in human embryonic stem cell-derived dopaminergic neurons: Implications for Parkinson's disease.
    Haynes JM; Sibuea SM; Aguiar AA; Li F; Ho JK; Pouton CW
    PLoS One; 2021; 16(12):e0261730. PubMed ID: 34941945
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.
    Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW
    Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033
    [TBL] [Abstract][Full Text] [Related]  

  • 72. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity.
    Shani V; Safory H; Szargel R; Wang N; Cohen T; Elghani FA; Hamza H; Savyon M; Radzishevsky I; Shaulov L; Rott R; Lim KL; Ross CA; Bandopadhyay R; Zhang H; Engelender S
    Hum Mol Genet; 2019 Dec; 28(23):3982-3996. PubMed ID: 31626293
    [TBL] [Abstract][Full Text] [Related]  

  • 74. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 76. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 77. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
    Kalogeropulou AF; Purlyte E; Tonelli F; Lange SM; Wightman M; Prescott AR; Padmanabhan S; Sammler E; Alessi DR
    Biochem J; 2022 Sep; 479(17):1759-1783. PubMed ID: 35950872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation.
    Madero-Pérez J; Fdez E; Fernández B; Lara Ordóñez AJ; Blanca Ramírez M; Gómez-Suaga P; Waschbüsch D; Lobbestael E; Baekelandt V; Nairn AC; Ruiz-Martínez J; Aiastui A; López de Munain A; Lis P; Comptdaer T; Taymans JM; Chartier-Harlin MC; Beilina A; Gonnelli A; Cookson MR; Greggio E; Hilfiker S
    Mol Neurodegener; 2018 Jan; 13(1):3. PubMed ID: 29357897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.